Gelteq Ltd
NASDAQ:GELS
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| AU |
G
|
Gelteq Ltd
NASDAQ:GELS
|
8.6m USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
989.2B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
573.4B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
281.1B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
302.9B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
230.9B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.1B GBP |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
154B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.3B USD |
Loading...
|
Market Distribution
| Min | -16 177 900% |
| 30th Percentile | -544.7% |
| Median | -27.7% |
| 70th Percentile | 3.1% |
| Max | 3 174 540% |
Other Profitability Ratios
Gelteq Ltd
Glance View
Gelteq Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Melbourne, Victoria. The company went IPO on 2024-10-29. Gelteq Limited is an Australia-based clinical and science-based company. The firm is focused on developing and commercializing white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. The firm offers a complete end-to-end service for the development of new products and the conversion of existing products and formulations into gels. Its product suite consists of multiple products that sit within five core verticals - for pets, sports, pharmaceuticals (pharma), over-the-counter (OTC) and nutraceuticals. The Company’s delivery system provides pharma and nutraceutical enhancements throughout every stage of ingestion in both animals and humans, addressing the complete experience from the point of ingestion to final absorption. The firm also offers a highly versatile portfolio of pre-tested and market-ready proprietary formulations that can be white-labelled.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Gelteq Ltd is -4 010.6%, which is below its 3-year median of -3 870.8%.
Over the last 2 years, Gelteq Ltd’s Net Margin has decreased from -3 208% to -4 010.6%. During this period, it reached a low of -4 393.7% on Jun 30, 2023 and a high of -3 208% on Mar 3, 2023.
